Teva Europe Portfolio Said to Draw Interest From Mylan, Novartis

Teva Pharmaceutical Industries Ltd.’s portfolio of drugs in the U.K., Ireland and Iceland is attracting bidders including Mylan NV and Novartis AG, people familiar with the matter said. Private equity firms including Apollo Global Management LLC and Cinven Ltd. are also weighing bids for the business, which could fetch $1.5 billion to $2 billion, the people said, asking not to be named because the deliberations are private.